This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Almac Discovery Limited. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Andrew Porter - Innovator in Antigen Binding Molecules
Introduction
Andrew Porter is a notable inventor based in Craigavon, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antigen binding molecules. His work focuses on innovative solutions that have the potential to impact therapeutic applications.
Latest Patents
Andrew Porter holds a patent for ROR1-specific antigen binding molecules. This invention relates to receptor tyrosine kinase-like orphan receptor 1 (ROR1) specific antigen binding molecules and associated fusion proteins and conjugates. Additionally, the patent includes conjugated immunoglobulin-like shark variable novel antigen receptors (VNARs). This patent showcases his expertise in creating targeted therapeutic agents.
Career Highlights
Andrew Porter is currently associated with Almac Discovery Limited, where he continues to advance his research and development efforts. His role at the company allows him to collaborate with other experts in the field and contribute to innovative projects.
Collaborations
Some of his coworkers include Estelle Grace McLean and Paul Richard Trumper. Their collaboration fosters a dynamic environment for research and innovation, enhancing the potential for groundbreaking discoveries.
Conclusion
Andrew Porter is a distinguished inventor whose work in antigen binding molecules exemplifies the intersection of science and innovation. His contributions are paving the way for advancements in therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile